SCHEMBL5126809

SCHEMBL5126809

Cc1c2c(=O)n(CCCNC(=O)OC(C)(C)C)c3cc4c(cc3c2nn1C1CCCCO1)CCC(=O)C4

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 3/20 0.39
DYRK1A Q13627 1/20 0.35
CNR2 P34972 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BRD4 O60885 3/20 0.33
PLK1 P53350 4/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14192079 0.87 ATR (0.37) ATRDYRK1ACNR2ALDH1A1MEN1
SCHEMBL6522341 0.84 ATR (0.43) ATRDYRK1ACNR2BRD4PLK1
SCHEMBL6517473 0.84 ATR (0.42) ATRDYRK1ACNR2ALDH1A1CYP2C19
SCHEMBL6509041 0.84 ATR (0.42) ATRDYRK1ACNR2ALDH1A1MEN1
SCHEMBL6511027 0.84 ATR (0.42) ATRDYRK1ACNR2BRD4PLK1
SCHEMBL6521803 0.84 PLK1 (0.44) ATRDYRK1ACNR2ALDH1A1BRD4
SCHEMBL6508889 0.84 ATR (0.42) ATRDYRK1ACNR2BRD4PLK1
SCHEMBL6511907 0.84 ATR (0.42) ATRDYRK1ACNR2CYP2D6CYP2C9
SCHEMBL6509760 0.84 ATR (0.42) ATRDYRK1ACNR2BRD4PLK1
SCHEMBL6512647 0.84 CNR2 (0.45) ATRDYRK1ACNR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114016-A1 Inhibitors of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-05-15 US disclosed
EP-1835918-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-09-26 EP disclosed
WO-2006074281-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114016-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B ATR 11/4885DYRK1A 634/4885CNR2 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.